In Response to the Letter From Gregor Bachmann-Harildstad
In Reply: We appreciate your insightful comments in regards to our manuscript on dickkopf-related protein 3 as a marker for cerebrospinal fluid (CSF). We acknowledge and appreciate your clarification on the ability to detect, in the laboratory, beta trace protein at very small sample sizes. Beta trace protein, although a good marker for CSF, continues to be limited as a clinical tool by the need for a specialized laboratory which limits the locations where it can be used for rapid diagnosis. Our goal was to introduce a new marker for CSF along with its specific multiclonal antibodies. We continue to progress in developing a lateral-flow immunoassay for dickkopf-related protein 3 along with, as suggested, clinical trials to hopefully support an Food and Drug Administration-approved, simple to use, point-of-care test for the detection of CSF.